Li MC, Hertz R, Bergenstal DM. Remedy of choriocarcinoma and associated trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958;259:66–74.
Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in persistent myelogenous leukaemia. Nature. 1985;315:550–4.
Kakizuka A, Miller WH Jr., Umesono Okay, Warrell RP Jr., Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription issue, PML. Cell. 1991;66:663–74.
van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Motion BMH4-CT98-3936. Leukemia. 2003;17:2257–317.
Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the suggestions for harmonizing present methodology for detecting BCR-ABL transcripts in sufferers with persistent myeloid leukaemia. Leukemia. 2006;20:1925–30.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 suggestions for treating persistent myeloid leukemia. Leukemia. 2020;34:966–84.
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Lengthy-term follow-up of the French Cease Imatinib (STIM1) examine in sufferers with persistent myeloid leukemia. J Clin Oncol. 2017;35:298–305.
Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Remedy-free remission following frontline nilotinib in sufferers with persistent myeloid leukemia in persistent section: outcomes from the ENESTfreedom examine. Leukemia. 2017;31:1525–31.
Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, et al. Remedy-free remission following frontline nilotinib in sufferers with persistent section persistent myeloid leukemia: 5-year replace of the ENESTfreedom trial. Leukemia. 2021;35:1344–55.
Gale RP, Chen J. How ought to we interpret conclusions of TKI-stopping research. Leukemia. 2023;37:2343–5.
Chen J, Gale RP. Response to Pfirrmann et al.‘s touch upon How ought to we interpret conclusions of TKI-stopping research. Leukemia. 2024;38:463–4.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Lack of main molecular response as a set off for restarting tyrosine kinase inhibitor remedy in sufferers with chronic-phase persistent myelogenous leukemia who’ve stopped imatinib after sturdy undetectable illness. J Clin Oncol. 2014;32:424–30.
Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and high quality management research of ‘real-time’ quantitative reverse transcriptase polymerase chain response of fusion gene transcripts for residual illness detection in leukemia—a Europe Towards Most cancers program. Leukemia. 2003;17:2318–57.
Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O. Minimal residual illness: what are the minimal necessities? J Clin Oncol. 2014;32:475–6.
Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory suggestions for scoring deep molecular responses following therapy for persistent myeloid leukemia. Leukemia. 2015;29:999–1003.
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. Worldwide Myeloma Working Group consensus standards for response and minimal residual illness evaluation in a number of myeloma. Lancet Oncol. 2016;17:e328–e46.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Replace on MRD in acute myeloid leukemia: a consensus doc from the European LeukemiaNet MRD Working Occasion. Blood. 2021;138:2753–67.
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Analysis and administration of AML in adults: 2022 suggestions from a world knowledgeable panel on behalf of the ELN. Blood. 2022;140:1345–77.
Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, et al. Affect of circulating tumor DNA-based detection of molecular residual illness on the conduct and design of medical trials for stable tumors. JCO Summary Oncol. 2022;6:e2100181.
Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, et al. Prognostic worth of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell inhabitants in sufferers allografted for acute myeloid leukaemia. Leukemia. 2015;29:988–91.
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, et al. Peri-transplant flow-MRD evaluation of cells with leukemic stem cells (LSC) related phenotype in AML sufferers present process allogeneic stem cell transplantation in CR. Leukemia. 2024;38:386–8.
Nakamura S, Yokoyama Okay, Shimizu E, Yusa N, Kondoh Okay, Ogawa M, et al. Prognostic influence of circulating tumor DNA standing post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019;133:2682–95.
Quick NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, et al. Focused next-generation sequencing of circulating cell-free DNA vs bone marrow in sufferers with acute myeloid leukemia. Blood Adv. 2020;4:1670–7.
Butturini A, Klein J, Gale RP. Modeling minimal residual illness (MRD)-testing. Leuk Res. 2003;27:293–300.
Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, et al. Polymerase chain response detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for persistent myeloid leukemia: outcomes and implications in 346 sufferers. Blood. 1995;85:2632–8.
Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani Okay, Cwynarski Okay, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain response predicts end result after allogeneic stem cell transplantation for persistent myeloid leukemia. Blood. 2001;97:1560–5.
Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic worth of minimal residual illness quantification earlier than allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Research Group. J Clin Oncol. 2009;27:377–84.
Othus M, Wooden BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, et al. Impact of measurable (‘minimal’) residual illness (MRD) data on prediction of relapse and survival in grownup acute myeloid leukemia. Leukemia. 2016;30:2080–3.
Estey E, Gale RP. How good are we at predicting the destiny of somebody with acute myeloid leukaemia? Leukemia. 2017;31:1255–8.
Garcia-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) evaluation into medical follow: alternatives and challenges. Br J Most cancers. 2022;127:592–602.
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. Excessive prognostic influence of stream cytometric minimal residual illness detection in acute myeloid leukemia: information from the HOVON/SAKK AML 42A examine. J Clin Oncol. 2013;31:3889–97.
Walter RB, Buckley SA, Pagel JM, Wooden BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual illness earlier than myeloablative allogeneic hematopoietic cell transplantation for AML in first and second full remission. Blood. 2013;122:1813–21.
Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, et al. Prognostic relevance of therapy response measured by stream cytometric residual illness detection in older sufferers with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–31.
Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, et al. The extent of residual illness primarily based on mutant NPM1 is an unbiased prognostic issue for relapse and survival in AML. Blood. 2013;122:83–92.
Ravandi F, Jorgensen JL, Thomas DA, O’Brien S, Garris R, Faderl S, et al. Detection of MRD could predict the end result of sufferers with Philadelphia chromosome-positive ALL handled with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–21.
Eckert C, Henze G, Seeger Okay, Hagedorn N, Mann G, Panzer-Grumayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation primarily based on minimal residual illness response improves outcomes for youngsters with relapsed acute lymphoblastic leukemia within the intermediate-risk group. J Clin Oncol. 2013;31:2736–42.
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Remedy discount for youngsters and younger adults with low-risk acute lymphoblastic leukaemia outlined by minimal residual illness (UKALL 2003): a randomised managed trial. Lancet Oncol. 2013;14:199–209.
Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, et al. Ph+ ALL sufferers in first full remission have related survival after diminished depth and myeloablative allogeneic transplantation: influence of tyrosine kinase inhibitor and minimal residual illness. Leukemia. 2014;28:658–65.
Kolstad A, Laurell A, Jerkeman M, Gronbaek Okay, Elonen E, Raty R, et al. Nordic MCL3 examine: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR sufferers earlier than transplant in mantle cell lymphoma. Blood. 2014;123:2953–9.
Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, et al. Early evaluation of minimal residual illness identifies sufferers at very excessive relapse danger in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123:334–7.
Beldjord Okay, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual illness are unbiased end result predictors in grownup sufferers with acute lymphoblastic leukemia. Blood. 2014;123:3739–49.
Hubmann M, Kohnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, et al. Molecular response evaluation by quantitative real-time polymerase chain response after induction remedy in NPM1-mutated sufferers identifies these at excessive danger of relapse. Haematologica. 2014;99:1317–25.
Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, fairly than c-KIT mutations, permits additional danger stratification. Blood. 2014;124:1880–6.
Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in kids with ALL: a section 3 Kids’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014;123:2017–25.
Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission remedy for a minimal residual disease-defined high-risk subgroup of youngsters and younger folks with medical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised managed trial. Lancet Oncol. 2014;15:809–18.
Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grumayer R, Peters C, et al. Monitoring minimal residual illness in kids with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late evaluation. Leukemia. 2015;29:1648–55.
Pulsipher MA, Carlson C, Langholz B, Wall DA, Schultz KR, Bunin N, et al. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and really high-risk ALL sufferers. Blood. 2015;125:3501–8.
Bader P, Kreyenberg H, von Stackelberg A, Eckert C, Salzmann-Manrique E, Meisel R, et al. Monitoring of minimal residual illness after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia permits for the identification of impending relapse: outcomes of the ALL-BFM-SCT 2003 trial. J Clin Oncol. 2015;33:1275–84.
Chen X, Xie H, Wooden BL, Walter RB, Pagel JM, Becker PS, et al. Relation of medical response and minimal residual illness and their prognostic influence on end result in acute myeloid leukemia. J Clin Oncol. 2015;33:1258–64.
Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, et al. Comparability of minimal residual illness as end result predictor for AML sufferers in first full remission present process myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137–44.
Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord Okay, Asnafi V, et al. Position of allogeneic stem cell transplantation in grownup sufferers with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486–96.
Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, et al. Minimal residual illness as biomarker for optimum biologic dosing of ARA-C in sufferers with acute myeloid leukemia. Am J Hematol. 2015;90:125–31.
Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Evaluation of minimal residual illness in standard-risk AML. N Engl J Med. 2016;374:422–33.
Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, et al. Potential long-term minimal residual illness monitoring utilizing RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: outcomes of the French CBF-2006 trial. Haematologica. 2016;101:328–35.
Araki D, Wooden BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to maneuver towards a minimal residual disease-based definition of full remission? J Clin Oncol. 2016;34:329–36.
Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, et al. Peripheral blood minimal residual illness could change bone marrow minimal residual illness as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2016;30:708–15.
Zhou Y, Othus M, Araki D, Wooden BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual illness by way of multiparameter stream cytometry in grownup acute myeloid leukemia. Leukemia. 2016;30:1456–64.
Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, et al. Pre-transplantation minimal residual illness with cytogenetic and molecular diagnostic options improves danger stratification in acute myeloid leukemia. Haematologica. 2017;102:110–7.
Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, et al. Combining stream cytometry and WT1 evaluation improves the prognostic worth of pre-transplant minimal residual illness in acute myeloid leukemia. Haematologica. 2017;102:e348–e51.
Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, et al. Postinduction minimal residual illness predicts end result and profit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a examine by the Acute Leukemia French Affiliation Group. J Clin Oncol. 2017;35:185–93.
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, et al. Relapse danger and survival in sufferers with FLT3 mutated acute myeloid leukemia present process stem cell transplantation. Am J Hematol. 2017;92:331–7.
Chang YJ, Zhao XS, Wang Y, Liu YR, Xu LP, Zhang XH, et al. Results of pre-and post-transplantation minimal residual illness on outcomes in pediatric sufferers with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched associated donor allografts. Am J Hematol. 2017;92:E659–E61.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, et al. Achievement of a damaging minimal residual illness state after hypomethylating agent remedy in older sufferers with AML reduces the chance of relapse. Leukemia. 2018;32:241–4.
Cazzaniga G, De Lorenzo P, Alten J, Rottgers S, Hancock J, Saha V, et al. Predictive worth of minimal residual illness in Philadelphia-chromosome-positive acute lymphoblastic leukemia handled with imatinib within the European intergroup examine of post-induction therapy of Philadelphia-chromosome-positive acute lymphoblastic leukemia, primarily based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103:107–15.
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual illness in acute myeloid leukemia. N. Engl J Med. 2018;378:1189–99.
Morita Okay, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki Okay, et al. Clearance of somatic mutations at remission and the chance of relapse in acute myeloid leukemia. J Clin Oncol. 2018;36:1788–97.
Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, et al. Oncogenetic mutations mixed with MRD enhance end result prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131:289–300.
Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, et al. Measurable residual illness at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in sufferers at customary danger with out NPM1 mutations. J Clin Oncol. 2018;36:1486–97.
Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, et al. Measurable residual illness monitoring by NGS earlier than allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703–13.
Schrappe M, Bleckmann Okay, Zimmermann M, Biondi A, Moricke A, Locatelli F, et al. Decreased-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia outlined by undetectable minimal residual illness: outcomes of a world randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.
Zhao XS, Liu YR, Xu LP, Wang Y, Zhang XH, Chen H, et al. Minimal residual illness standing decided by multiparametric stream cytometry pretransplantation predicts the end result of sufferers with ALL receiving unmanipulated haploidentical allografts. Am J Hematol. 2019;94:512–21.
Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, et al. CD34(+)CD38(-) leukemic stem cell frequency to foretell end result in acute myeloid leukemia. Leukemia. 2019;33:1102–12.
Rucker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, et al. Measurable residual illness monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): outcomes from the AML Research Group. Blood. 2019;134:1608–18.
Modvig S, Madsen HO, Siitonen SM, Rosthoj S, Tierens A, Juvonen V, et al. Minimal residual illness quantification by stream cytometry gives dependable danger stratification in T-cell acute lymphoblastic leukemia. Leukemia. 2019;33:1324–36.
Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS management of childhood acute lymphoblastic leukemia with out cranial irradiation: St Jude Complete Remedy Research 16. J Clin Oncol. 2019;37:3377–91.
Morsink LM, Othus M, Bezerra ED, Wooden BL, Fang M, Sandmaier BM, et al. Affect of pretransplant measurable residual illness on the end result of allogeneic hematopoietic cell transplantation in grownup monosomal karyotype AML. Leukemia. 2020;34:1577–87.
Baron F, Labopin M, Ruggeri A, Sierra J, Robinson S, Labussiere-Pockets H, et al. Affect of detectable measurable residual illness on umbilical twine blood transplantation. Am J Hematol. 2020;95:1057–65.
Paiva B, Puig N, Cedena MT, Rosinol L, Cordon L, Vidriales MB, et al. Measurable residual illness by next-generation stream cytometry in a number of myeloma. J Clin Oncol. 2020;38:784–92.
Perez-Martinez A, Ferreras C, Pascual A, Gonzalez-Vicent M, Alonso L, Badell I, et al. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative evaluation on behalf of the Spanish working Group for bone marrow transplantation in kids (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2020;95:28–37.
Morsink LM, Bezerra ED, Othus M, Wooden BL, Fang M, Sandmaier BM, et al. Comparative evaluation of whole physique irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or with out measurable residual illness. Leukemia. 2020;34:1701–5.
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Affect of conditioning depth of allogeneic transplantation for acute myeloid leukemia with genomic proof of residual illness. J Clin Oncol. 2020;38:1273–83.
Zhou B, Chu X, Tian H, Liu T, Liu H, Gao W, et al. The medical outcomes and genomic landscapes of acute lymphoblastic leukemia sufferers with E2A-PBX1: A ten-year retrospective examine. Am J Hematol. 2021;96:1461–71.
Paiva B, Vidriales MB, Sempere A, Tarin F, Colado E, Benavente C, et al. Affect of measurable residual illness by decentralized stream cytometry: a PETHEMA real-world examine in 1076 sufferers with acute myeloid leukemia. Leukemia. 2021;35:2358–70.
Cho BS, Min GJ, Park S, Park SS, Shin SH, Yahng SA, et al. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A potential comparative examine. Am J Hematol. 2021;96:98–109.
Sidhom I, Shaaban Okay, Youssef SH, Ali N, Gohar S, Rashed WM, et al. Decreased-intensity remedy for pediatric lymphoblastic leukemia: influence of residual illness early in remission induction. Blood. 2021;137:20–8.
Esteve J, Giebel S, Labopin M, Czerw T, Wu D, Volin L, et al. Allogeneic hematopoietic stem cell transplantation for grownup sufferers with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first full remission: influence of pretransplant measurable residual illness (MRD) standing. An evaluation from the Acute Leukemia Working Occasion of the EBMT. Leukemia. 2021;35:2232–42.
Jentzsch M, Grimm J, Invoice M, Brauer D, Backhaus D, Pointner R, et al. Medical worth of the measurable residual illness standing inside the ELN2017 danger teams in AML sufferers present process allogeneic stem cell transplantation. Am J Hematol. 2021;96:E237–E9.
den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, et al. Outcomes of paediatric sufferers with B-cell acute lymphocytic leukaemia with ABL-class fusion within the pre-tyrosine-kinase inhibitor period: a multicentre, retrospective, cohort examine. Lancet Haematol. 2021;8:e55–e66.
Patkar N, Kakirde C, Shaikh AF, Salve R, Bhanshe P, Chatterjee G, et al. Medical influence of panel-based error-corrected subsequent technology sequencing versus stream cytometry to detect measurable residual illness (MRD) in acute myeloid leukemia (AML). Leukemia. 2021;35:1392–404.
Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, et al. Measurable residual illness monitoring gives inadequate lead-time to forestall morphologic relapse within the majority of sufferers with core-binding issue acute myeloid leukemia. Haematologica. 2021;106:56–63.
Modvig S, Hallbook H, Madsen HO, Siitonen S, Rosthoj S, Tierens A, et al. Worth of stream cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting. Leukemia. 2021;35:1894–906.
Mattano LA Jr., Devidas M, Maloney KW, Wang C, Friedmann AM, Buckley P, et al. Favorable trisomies and ETV6-RUNX1 predict remedy in low-risk B-cell acute lymphoblastic leukemia: outcomes from Kids’s Oncology Group trial AALL0331. J Clin Oncol. 2021;39:1540–52.
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity routine doesn’t enhance postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768–78.
Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, et al. Pulse remedy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, section 3, non-inferiority trial. Lancet Oncol. 2021;22:1322–32.
Popov A, Henze G, Roumiantseva J, Budanov O, Belevtsev M, Verzhbitskaya T, et al. A easy algorithm with one stream cytometric MRD measurement identifies greater than 40% of youngsters with ALL who might be cured with low-intensity remedy. The ALL-MB 2008 trial outcomes. Leukemia. 2022;36:1382–5.
Marks DI, Clifton-Hadley L, Copland M, Hussain J, Menne TF, McMillan A, et al. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for sufferers with acute lymphoblastic leukaemia in first remission: outcomes from the possible, single-arm analysis of the UKALL14 trial. Lancet Haematol. 2022;9:e276–e88.
Escherich G, Zur Stadt U, Borkhardt A, Dilloo D, Faber J, Feuchtinger T, et al. Clofarabine will increase the eradication of minimal residual illness of main B-precursor acute lymphoblastic leukemia in comparison with high-dose cytarabine with out enchancment of end result. Outcomes from the randomized medical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Research Group. Haematologica. 2022;107:1026–33.
Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning depth and peritransplant stream cytometric MRD dynamics in grownup AML. Blood. 2022;139:1694–706.
Li SQ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. An LSC-based MRD assay to enhance the normal MFC methodology for prediction of AML relapse: a potential examine. Blood. 2022;140:516–20.
Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, et al. Time to remedy for childhood and younger grownup acute lymphoblastic leukemia is unbiased of early danger elements: long-term follow-up of the UKALL2003 trial. J Clin Oncol. 2022;40:4228–39.
Attarbaschi A, Moricke A, Harrison CJ, Mann G, Baruchel A, De Moerloose B, et al. Outcomes of childhood noninfant acute lymphoblastic leukemia with 11q23/KMT2A rearrangements in a contemporary remedy period: a retrospective worldwide examine. J Clin Oncol. 2023;41:1404–22.
Wooden B, Devidas M, Summers RJ, Chen Z, Asselin BL, Rabin KR, et al. Prognostic significance of ETP phenotype and minimal residual illness in T-ALL: a Kids’s Oncology Group Research. Blood. 2023;142:2069–78.
Orvain C, Wilson JA, Fang M, Sandmaier BM, Rodriguez-Arboli E, Wooden BL, et al. Relative influence of residual cytogenetic abnormalities and stream cytometric measurable residual illness on end result after allogeneic hematopoietic cell transplantation in grownup acute myeloid leukemia. Haematologica. 2023;108:420–32.
Dillon LW, Gui G, Web page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA Sequencing to Detect Residual Illness in Adults With Acute Myeloid Leukemia Previous to Hematopoietic Cell Transplant. JAMA. 2023;329:745–55.
Othman J, Tiong IS, O’Nions J, Dennis M, Mokretar Okay, Ivey A, et al. Molecular MRD is strongly prognostic in sufferers with NPM1-mutated AML receiving venetoclax-based non-intensive remedy. Blood. 2023;143:336–41.
Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, et al. Quantification of measurable residual illness utilizing duplex sequencing in adults with acute myeloid leukemia. Haematologica. 2024;109:401–10.
Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, et al. Prognostic significance of measurable residual illness in sufferers with acute lymphoblastic leukemia present process allogeneic hematopoietic stem cell transplantation in second or later full remission. Am J Hematol. 2023;98:E35–E7.
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, et al. Genetic alterations and MRD refine danger evaluation for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL examine. Blood. 2023;142:1806–17.
van Weelderen RE, Klein Okay, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, et al. Measurable residual illness and fusion associate independently predict survival and relapse danger in childhood KMT2A-rearranged acute myeloid leukemia: a examine by the Worldwide Berlin-Frankfurt-Munster Research Group. J Clin Oncol. 2023;41:2963–74.
Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, et al. Prognostic worth of FLT3-internal tandem duplication residual illness in acute myeloid leukemia. J Clin Oncol. 2023;41:756–65.
Ariffin H, Chiew EKH, Oh BLZ, Lee SHR, Lim EH, Kham SKY, et al. Anthracycline-free protocol for favorable-risk childhood ALL: a noninferiority comparability between Malaysia-Singapore ALL 2003 and ALL 2010 research. J Clin Oncol. 2023;41:3642–51.
Campbell M, Kiss C, Zimmermann M, Riccheri C, Kowalczyk J, Felice MS, et al. Childhood acute lymphoblastic leukemia: outcomes of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-Munster 2009 trial. J Clin Oncol. 2023;41:3499–511.
Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts RJ, et al. Evaluation of molecular relapse detection in early-stage breast most cancers. JAMA Oncol. 2019;5:1473–8.
Christensen E, Birkenkamp-Demtroder Okay, Sethi H, Shchegrova S, Salari R, Nordentoft I, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in sufferers with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547–57.
Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal most cancers. JAMA Oncol. 2019;5:1118–23.
Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma utilizing circulating tumor DNA. Ann Oncol. 2019;30:804–14.
Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Evaluation of plasma cell-free DNA by ultradeep sequencing in sufferers with phases I to III colorectal most cancers. JAMA Oncol. 2019;5:1124–31.
Tie J, Cohen JD, Wang Y, Christie M, Simons Okay, Lee M, et al. Circulating tumor DNA analyses as markers of recurrence danger and good thing about adjuvant remedy for stage III colon most cancers. JAMA Oncol. 2019;5:1710–7.
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, et al. Affiliation of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with illness recurrence in sufferers with triple-negative breast most cancers: preplanned secondary evaluation of the BRE12-158 randomized medical trial. JAMA Oncol. 2020;6:1410–5.
Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast most cancers displays response and survival. Ann Oncol. 2021;32:229–39.
Ococks E, Frankell AM, Masque Soler N, Grehan N, Northrop A, Coles H, et al. Longitudinal monitoring of 97 esophageal adenocarcinomas utilizing liquid biopsy sampling. Ann Oncol. 2021;32:522–32.
Lipsyc-Sharf M, de Bruin EC, Santos Okay, McEwen R, Stetson D, Patel A, et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal progress issue receptor 2-negative breast most cancers. J Clin Oncol. 2022;40:2408–19.
Gale D, Heider Okay, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, et al. Residual ctDNA after therapy predicts early relapse in sufferers with early-stage non-small cell lung most cancers. Ann Oncol. 2022;33:500–10.
Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual illness and efficacy of adjuvant chemotherapy in sufferers with colorectal most cancers. Nat Med. 2023;29:127–34.
Mo S, Ye L, Wang D, Han L, Zhou S, Wang H, et al. Early detection of molecular residual illness and danger stratification for stage I to III colorectal most cancers by way of circulating tumor DNA methylation. JAMA Oncol. 2023;9:770–8.
Takahashi N, Nishiwaki Okay, Nakaseko C, Aotsuka N, Sano Okay, Ohwada C, et al. Remedy-free remission after two-year consolidation remedy with nilotinib in sufferers with persistent myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103:1835–42.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell Okay, Pocock C, et al. De-escalation of tyrosine kinase inhibitor remedy earlier than full therapy discontinuation in sufferers with persistent myeloid leukaemia (DESTINY): a non-randomised, section 2 trial. Lancet Haematol. 2019;6:e375–e83.
Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, et al. Evaluation of outcomes after stopping tyrosine kinase inhibitors amongst sufferers with persistent myeloid leukemia: a nonrandomized medical trial. JAMA Oncol. 2021;7:42–50.
Galbraith RF. A notice on graphical presentation of estimated odds ratios from a number of medical trials. Stat Med. 1988;7:889–94.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a easy, graphical take a look at. BMJ. 1997;315:629–34.
Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Affiliation of minimal residual illness with medical end result in pediatric and grownup acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.
Quick NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Affiliation of measurable residual illness with survival outcomes in sufferers with acute myeloid leukemia: a scientific evaluation and meta-analysis. JAMA Oncol. 2020;6:1890–9.
O’Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, et al. Genotype-specific minimal residual illness interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36:34–43.
Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Ostergaard M, et al. Strikingly totally different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115:198–205.
Music J, Mercer D, Hu X, Liu H, Li MM. Widespread leukemia- and lymphoma-associated genetic aberrations in wholesome people. J Mol Diagn. 2011;13:213–9.
Younger AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in wholesome adults. Nat Commun. 2016;7:12484.
Walia A, Tuia J, Prasad V. Development-free survival, disease-free survival and different composite finish factors in oncology: improved reporting is required. Nat Rev Clin Oncol. 2023;20:885–95.
Juul-Dam KL, Ommen HB, Nyvold CG, Walter C, Valerhaugen H, Kairisto V, et al. Measurable residual illness evaluation by qPCR in peripheral blood is an informative instrument for illness surveillance in childhood acute myeloid leukaemia. Br J Haematol. 2020;190:198–208.
Lew TE, Anderson MA, Lin VS, Handunnetti SM, Got here NA, Blombery P, et al. Undetectable peripheral blood MRD ought to be the purpose of venetoclax in CLL, however attainment plateaus after 24 months. Blood Adv. 2020;4:165–73.
Veltmaat N, Zhong Y, de Jesus FM, Tan GW, Bult JAA, Terpstra MM, et al. Genomic profiling of post-transplant lymphoproliferative problems utilizing cell-free DNA. J Hematol Oncol. 2023;16:104.
Feng Y, Qi S, Liu X, Zhang L, Hu Y, Shen Q, et al. Have we been qualifying measurable residual illness appropriately? Leukemia. 2023;37:2168–72.
Chen J. Response to touch upon Have we been qualifying measurable residual illness appropriately? Leukemia. 2024;38:219–20.
Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, variations and medical prospects in CML and AML. Nat Rev Most cancers. 2020;20:158–73.
Zhang B, Li L, Ho Y, Li M, Marcucci G, Tong W, et al. Heterogeneity of leukemia-initiating capability of persistent myelogenous leukemia stem cells. J Clin Make investments. 2016;126:975–91.
Polivkova V, Benesova A, Zizkova H, Koblihova J, Curik N, Motlova E, et al. Sensitivity and reliability of DNA-based mutation evaluation by allele-specific digital PCR to observe resistant BCR-ABL1-positive cells. Leukemia. 2021;35:2419–23.
Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl J Med. 2004;351:657–67.
Kinstrie R, Karamitros D, Goardon N, Morrison H, Hamblin M, Robinson L, et al. Heterogeneous leukemia stem cells in myeloid blast section persistent myeloid leukemia. Blood Adv. 2016;1:160–9.
Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a “shifting goal” for detection of residual illness. Cytom B Clin Cytom. 2014;86:3–14.
Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, et al. Speedy enlargement of preexisting nonleukemic hematopoietic clones incessantly follows induction remedy for de novo AML. Blood. 2016;127:893–7.
Liu LP, Zong SY, Zhang AL, Ren YY, Qi BQ, Chang LX, et al. Early detection of molecular residual illness and danger stratification for youngsters with acute myeloid leukemia by way of circulating tumor DNA. Clin Most cancers Res. 2024;30:1143–51.
Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual illness in AML: a consensus doc from the European LeukemiaNet MRD Working Occasion. Blood. 2018;131:1275–91.
Buccisano F, Palmieri R, Piciocchi A, Enviornment V, Maurillo L, Del Principe MI, et al. Medical relevance of an goal stream cytometry method primarily based on restrict of detection and restrict of quantification for measurable residual illness evaluation in acute myeloid leukemia. A post-hoc evaluation of the GIMEMA AML1310 trial. Haematologica. 2022;107:2823–33.
Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, et al. Comparability of next-generation sequencing (NGS) and next-generation stream (NGF) for minimal residual illness (MRD) evaluation in a number of myeloma. Blood Most cancers J. 2020;10:108.
Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, et al. Minimal residual illness (MRD) evaluation within the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it attainable to keep away from MRD testing? Leukemia. 2008;22:989–97.
Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, et al. Monitoring therapy response of childhood precursor B-cell acute lymphoblastic leukemia within the AIEOP-BFM-ALL 2000 protocol with multiparameter stream cytometry: predictive influence of early blast discount on the remission standing after induction. Leukemia. 2009;23:528–34.
Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Danger of relapse of childhood acute lymphoblastic leukemia is predicted by stream cytometric measurement of residual illness on day 15 bone marrow. J Clin Oncol. 2009;27:5168–74.
Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia with out cranial irradiation. N. Engl J Med. 2009;360:2730–41.
Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, et al. Consequence of youngsters with hypodiploid ALL handled with risk-directed remedy primarily based on MRD ranges. Blood. 2015;126:2896–9.
Campana D, Pui CH. Minimal residual disease-guided remedy in childhood acute lymphoblastic leukemia. Blood. 2017;129:1913–8.
Cohen SA, Liu MC, Aleshin A. Sensible suggestions for utilizing ctDNA in medical choice making. Nature. 2023;619:259–68.
Venditti A, Gale RP, Buccisano F, Ossenkoppele G. Ought to individuals with acute myeloid leukemia (AML) in 1st histological full remission who’re measurable residual illness (MRD) take a look at constructive obtain an allotransplant? Leukemia. 2020;34:963–5.
Prentice RL. Surrogate endpoints in medical trials: definition and operational standards. Stat Med. 1989;8:431–40.
